A B S T R A C T

Background
Pneumocystis jiroveci pneumonia (PCP) remains the most common opportunistic infection in patients infected with the human immunodeficiency virus (HIV). Among patients with HIV infection and PCP the mortality rate is 10 to 20% during the initial infection and increases substantially with the need for mechanical ventilation. It was suggested that in these patients corticosteroids adjunctive to standard treatment for PCP could prevent the need for mechanical ventilation and decrease mortality.
Objectives
To assess the effects of adjunctive corticosteroids on overall mortality and the need for mechanical ventilation in HIV-infected patients with PCP and substantial hypoxemia (arterial oxygen partial pressure <70 mmHg or alveolar-arterial gradient >35 mmHg on room air).
Search methods
We searched Medline (January 1980 -December 2004 , EMBASE (January 1985 -December 2004 and The Cochrane Library (Issue 4, 2004) without language restrictions to identify randomised controlled trials that compared adjunctive corticosteroids to control in HIV-infected patients with PCP. We further reviewed the reference lists from previously published overviews, we searched UptoDate version 2005 and Clinical Evidence Concise (Issue 12, 2004) , contacted experts of the field, and searched reference lists of identified publications for citations of additional relevant articles.
Selection criteria
Trials were considered eligible for this review if they compared corticosteroids to placebo or usual care in HIV-infected patients with PCP in addition to baseline treatment with trimethoprim-sulfamethoxazole, pentamidine or dapsone-trimethoprim, used random allocation, and reported mortality data. We excluded trials in patients with no or mild hypoxemia (arterial oxygen partial pressure >70 mmHg or an alveolar-arterial gradient <35 mmHg on room air) and trials with a follow-up of less than 30 days.
Data collection and analysis
Two teams of reviewers independently evaluated the methodology and extracted data from each primary study. We pooled treatment effects across studies and calculated a weighted average risk ratio of overall mortality in the treatment and control groups by using a random effects model.
Main results
Six studies were included in the review and meta-analysis. Risk ratios for overall mortality for adjunctive corticosteroids were 0.56 (95% confidence interval [CI] , 0.32-0.98) at 1 month and 0.68 (95% CI, 0.50-0.94) at 3-4 months of follow-up. To prevent 1 death, numbers needed to treat are 9 patients in a setting without highly active antiretroviral therapy (HAART) available, and 23 patients with HAART available. Only the 3 largest trials provided data on the need for mechanical ventilation with a risk ratio of 0.38 (95% CI, 0.20-0.73) in favour of adjunctive corticosteroids.
Authors' conclusions
The number and size of trials investigating adjunctive corticosteroids for HIV-infected patients with PCP is small, but evidence from this review suggests a beneficial effect for patients with substantial hypoxemia.
P L A I N L A N G U A G E S U M M A R Y
Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection
Pneumocystis jiroveci pneumonia (PCP), formerly called Pneumocystis carinii pneumonia, is the most common opportunistic infection among patients infected with HIV. In 1990, based on evidence from five randomized control trials, an expert panel recommended the use of corticosteroids for HIV-infected patients with PCP and substantial hypoxemia (low levels of oxygen in the blood). The objective of this systematic review was to assess the effects of adjunctive corticosteroids on mortality, and the need for mechanical ventilation in patients co-infected with HIV and PCP. Six studies were included in this review and meta-analysis. While the number and size of the trials investigating adjunctive corticosteroids for HIV-infected patients co-infected with PCP is small, evidence from this review suggests a beneficial effect for patients with substantial hypoxemia.
B A C K G R O U N D
With the introduction of highly active antiretroviral therapy (HAART) more than a decade ago, the incidence of Pneumocystis jiroveci pneumonia (PCP) (Stringer 2002) has decreased significantly in the Western hemisphere. However, PCP still remains the most common opportunistic infection in patients infected with the human immunodeficiency virus (HIV) (Kaplan 2000) . Among patients with HIV infection and PCP the mortality rate is 10 to 20% during the initial infection and increases substantially with the need for mechanical ventilation (Randall 2000) . In 1990, an expert panel recommended the use of corticosteroids for HIV-infected patients with PCP and substantial hypoxemia (initial arterial oxygen partial pressure of <70 mmHg or alveolararterial gradient >35 mmHg on room air) based on the evidence from five randomised controlled trials (Consensus 1990) . This consensus statement still represents the basis of current treatment guidelines (Benson 2004) . However, at the time this statement was made, one trial was not yet completed (Nielsen 1992), two trials were stopped prematurely (Gagnon 1990; Montaner 1990) , and one trial was not published in full (Clement 1989) . In 1992, a systematic review qualitatively summarised the same incomplete data (Sistek 1992).
O B J E C T I V E S
The objectives of this systematic review and meta-analysis of randomised controlled trials were to assess the magnitude of effects of adjunctive corticosteroid therapy on overall mortality and the need for mechanical ventilation in HIV-related PCP. In addition, we provide numbers needed to prevent one death that may serve as estimates for the expected benefit of adjunctive corticosteroid therapy in the presence and absence of HAART.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Trials were considered eligible for this review if they used random allocation of participants into parallel groups and reported mortality data. Trials with a follow-up of less than 30 days were excluded.
Types of participants
All HIV-infected patients with PCP and substantial hypoxemia. Patients without or mild hypoxemia (arterial oxygen partial pressure >70 mmHg or an alveolar-arterial gradient <35 mmHg on room air) were excluded.
Types of interventions
Studies were included if they compared corticosteroids to placebo or usual care in HIV-infected patients with PCP in addition to baseline treatment with trimethoprim-sulfamethoxazole, pentamidine or dapsone-trimethoprim.
Types of outcome measures
The main outcome measure of interest was overall mortality at 1 and 3-4 months of follow-up. A secondary outcome measure was the need for mechanical ventilation.
Search methods for identification of studies
We searched MEDLINE (January 1985 -December 2004 , EM-BASE (January 1985 -December 2004 and the Cochrane Library (Issue 4, 2004) without language restrictions to identify randomised controlled trials that compared adjunctive corticosteroids to control in HIV-infected patients with PCP. We used the terms steroid*, corticosteroid*, glucocorticoid*, Pneumocystis, PCP, *carinii, *jiroveci as text words and Glucocorticoids, Adrenal Cortex Hormones, Steroids, Pneumocystis Infections, Pneumocystis jiroveci, and Pneumonia, Pneumocystis as Medical Subject Headings. We restricted the search to articles indexed as randomised controlled trials (publication type) or drug therapy (subject heading) or those that included the words random* or placebo in their titles or abstracts. We further reviewed the reference lists from previously published overviews (Consensus 1990; Sistek 1992) 
Data collection and analysis
Two teams of investigators (MB/HCB and RB/HF) independently assessed study eligibility and quality and resolved any disagreement by consensus. Data of eligible trials were abstracted in duplicate. We assessed the quality of included trials with respect to concealment of treatment allocation; blinding of patients, caregivers or assessors of clinical outcomes; completeness of followup; performance of a sample size calculation; and if the trial was stopped early for benefit (Juni 1999; Montori 2005) .
Statistical analysis: All analyses were performed according to the intent-to-treat principle. We pooled treatment effects across studies and calculated a weighted average risk ratio of overall mortality in the treatment and control groups by using a random effects model. We investigated the presence of publication bias by means of funnel plots (Sterne 2001). We tested for heterogeneity with the Cochrane Q test and measured inconsistency (I2; the percentage of total variance across studies that is due to heterogeneity rather than chance) of treatment effects across studies (Higgins 2002; Higgins 2003) . We carried out sensitivity analyses to examine treatment effects according to quality components of trials, and if publication was as a peer-reviewed article or just in abstract form. Numbers needed to treat to prevent 1 death were calculated by multiplying the mean relative risk reduction with an initial mean baseline risk (Marx 2003) . Statistical analyses were performed using Stata 8.2 (StataCorp, College Station, Texas) and Rev Man 4.2.
R E S U L T S Description of studies
See: Characteristics of included studies; Characteristics of excluded studies. We identified 8 trials that met our inclusion criteria. We excluded one trial (Jeantils 1993) because it investigated only patients with mild hypoxemia and had a short follow-up of only 3 days, and another trial (Montaner 1993) which was a subgroup analysis of a larger included trial (Montaner 1990) . Of the remaining six trials, one was only published in abstract form (Clement 1989), two were stopped prematurely due to apparent benefits in the treatment goups with adjunctive glucocorticoid therapy (Montaner 1990; Gagnon 1990) , and one was stopped early due to published evidence from other studies in favor of adjunctive corticosteroids (Nielsen 1992) . Only three studies were completed and published in full version (Bozzette 1990; Nielsen 1992; Walmsley 1995 
Risk of bias in included studies
The quality assessment for each study is listed in the Table of Included Studies. Overall, the methodological quality of the six included studies was heterogenous. An exception was patient follow-up which was complete for all included studies due to short follow-up periods. Concealed allocation of participants was reported for three studies (Montaner 1990; Bozzette 1990; Walmsley 1995) . None of the studies reported to have assessed clinical outcomes in a blinded fashion, four trials reported blinding of care-givers and patients (Montaner 1990; Clement 1989; Gagnon 1990; Walmsley 1995) , three were single-center (Clement 1989; Montaner 1990; Gagnon 1990 ) and three multi-center studies (Bozzette 1990; Nielsen 1992; Walmsley 1995) , four trials reported the performance of a sample size calculation (Montaner 1990; Bozzette 1990; Gagnon 1990; Walmsley 1995) , and two trials were stopped prematurely due to apparent treatment benefits of adjunctive corticosteroids (Montaner 1990; Gagnon 1990) . The stopping early of clinical trials for benefit may lead to an overestimation of treatment effects due to catching the apparent benefit of treatment at a "random high" (Montori 2005).
Effects of interventions
There were six trials included in the systematic review and metaanalysis with a total of 242 individuals in the intervention groups and 247 individuals in the control groups. The Figure 1 indicated no evidence of a publication bias. Figure 1 . funnel plot.Funnel plot to evaluate the presence of a publication bias in trials investigating adjunctive corticosteroids for pneumocystis jiroveci pneumonia in HIV-infected patients. The funnel graph plots the log of the treatment odds ratio against the standard error (s.e.) of the log odds ratio (an indicator of sample size). Open circles represent trials included in the meta-analysis. The line in the centre indicates the summary log odds ratio. In the absence of a publication bias, the log odds ratio estimates from smaller trials are expected to be scattered above and below the summary estimate, producing a symmetric triangular or funnel shape. When smaller trials with larger log odds ratios are missing, the funnel plot appears asymmetric and may indicate the presence of a publication bias. In our systematic review the funnel plot looks symmetric.
The Egger test for publication bias was not statistically significant (P = 0.91).
Overall mortality Risk ratios for overall mortality were significantly reduced for adjunctive corticosteroids at 1 month (0.56;95% CI, 0. 
D I S C U S S I O N
This systematic review of 6 randomised controlled trials in HIVinfected patients with PCP and substantial hypoxemia found a significant reduction in the relative risk of death for adjunctive corticosteroids of 44% at 1 month and of 32% at 3-4 months. The average-weighted mean mortality in control groups of included trials at one month was 25%. This initial mortality-rate of 25% can be assumed in settings where HAART is not available which is still the case for most developing countries (Fisk 2003) . In this situation we estimated that 9 (95% CI, 6-200) HIV-infected patients with PCP have to be treated early with adjunctive corticosteroids to prevent 1 death during the first month after PCP diagnosis. In Western countries, where HAART is widely available, the respective number to treat was estimated to be 23 (95% CI, 15-500) patients assuming an initial mortality rate of 10% (Sepkowitz 2002) . With regard to the need for mechanical ventilation the risk reduction for adjunctive corticosteroids was even greater in the investigated patient population, but the number of trials was small (n=3).
This review has several strengths and limitations. We conducted an extensive literature search to retrieve all eligible trials. However, formal testing for publication bias was not powerful because of the small number of included trials. Even with a symmetric Figure 1 , such bias cannot be ruled out. Moreover, with a small number of included trials the uncertainty interval for the inconsistency among trials may not be very informative (Higgins 2003) . We focused mainly on mortality data that may be less prone to ascertainment bias, and we analysed the data according to the intent-to-treat principle to get more conservative estimates. Finally, the trials included in this meta-analysis used different corticosteroid regimen. So far, neither the dosing nor the length and tapering schedule of corticosteroids has been adequately addressed in randomised trials. In current recommendations (Benson 2004) the corticosteroid schedule of the largest trial (Bozzette 1990) was adapted.
There has been some concern among physicians treating patients with AIDS that further immunosuppression due to corticosteroid therapy could accelerate the onset of other HIV-related opportunistic complications (Lambertus 1990; Nelson 1993) . However, with the exception of an increase in muco-cutaneous herpes simplex infection episodes (Bozzette 1990), adjunctive corticosteroids were not associated with an increase in opportunistic complications in any of the included trials. A large cohort study which used a standard 21-day tapering course of adjunctive corticosteroids found no difference in the risk of AIDS-related complications apart from an increase in esophageal candidiasis (Gallant 1998).
It is possible that adjunctive corticosteroids are also beneficial for HIV-infected patients with mild hypoxemia due to PCP (Jeantils 1993). However, in this situation the short term mortality is low and possible unfavourable effects of corticosteroids might outweigh the benefits. Moreover, while corticosteroids might also be beneficial for non-HIV-infected patients with severe PCP (Pareja 1998), evidence from randomised controlled trials is still lacking.
A U T H O R S ' C O N C L U S I O N S Implications for practice
This systematic review confirmed and quantified the benefit of adjunctive corticosteroid therapy in HIV-infected patients with moderate-severe PCP. We estimated a relative risk reduction for overall mortality of 44% at 1 month and 32% at 3-4 months. We calculated that 9 patients must be treated with adjunctive corticosteroid in order to prevention one death in a setting where HAART is not available, and that 23 patients must be treated with adjunctive corticosteroid to prevent 1 death in a setting where HAART available.. The results underline the conclusions of the early released consensus statement (Consensus 1990) , and support current recommendations for the management of PCP in HIVinfected patients (Benson 2004) .
Implications for research
This systematic review confirmed and quantified the benefit of adjunctive corticosteroid therapy in HIV-infected patients with moderate-severe PCP. The results underline the conclusions of the early released consensus statement (Consensus 1990) , and support current recommendations for the management of PCP in HIVinfected patients (Benson 2004).
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